[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6215 followers
Created: 2025-07-28 09:34:23 UTC

Ajanta Pharma Q1 FY26 Results: XX% Revenue Growth & Strong Cash Flow 💰📈 | MCap XXXXXXXXX Cr

- Revenue up XX% YoY to ₹1,303 Cr (vs ₹1,145 Cr in Q1 FY25)
- EBITDA grew X% to ₹351 Cr (27% margin); PAT rose X% to ₹255 Cr (20% margin)
- Excluding ₹25 Cr forex loss: EBITDA would've grown XX% to ₹376 Cr, PAT up XX%
- Strong cash flow: CFO at ₹282 Cr (80% conversion), FCF at ₹209 Cr (82% of PAT)
- ROCE 33%, RONW XX%
- Market growth: India +16%, Asia +10%, Africa -1%, US generics +36%
- R&D spend: ₹56 Cr (4% of revenue)
- ANDA status: XX commercialized, XX awaiting US FDA approval

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of XX pages)

![](https://pbs.twimg.com/media/Gw71Hr8aYAEyWca.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1949765369058746636/c:line.svg)

**Related Topics**
[forex](/topic/forex)
[mcap](/topic/mcap)
[cash flow](/topic/cash-flow)
[quarterly earnings](/topic/quarterly-earnings)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1949765369058746636)